Dabogratinib's 57% Response Miss Exposes Competitive Gap, But FGFR3-Selective Niche Survives

Tyra's Dabogratinib Phase 2 Bladder Cancer Data Misses Expectations

Tyra Biosciences' shares dropped nearly 20% after its experimental bladder cancer drug, dabogratinib, achieved a 57% complete response rate in a Phase 2 trial, falling short of the company's internal expectation of 70%. The oral drug is being developed for non-muscle invasive bladder cancer driven by FGFR3 mutations, aiming to offer a convenient alternative to invasive treatments like UroGen Pharma's Zusduri (78% remission) and Johnson & Johnson's Balversa (89% remission in a similar setting). Despite the initial market reaction, analysts see a path forward for dabogratinib, particularly in an adjuvant Phase 3 trial targeting patients with a single marker lesion, citing its favorable safety profile.

• Tyra Biosciences reported that its investigational oral drug, dabogratinib, achieved a 57% complete response rate after three months in a Phase 2 trial for non-muscle invasive bladder cancer patients with FGFR3 mutations. This outcome was below the company's anticipated 70% complete response, leading to a nearly 20% decline in Tyra's stock value following the announcement.
• Dabogratinib is positioned as a convenient, once-daily oral alternative to existing invasive treatments for bladder cancer, such as UroGen Pharma's Zusduri, which requires weekly catheter-delivered chemotherapy and showed a 78% remission rate. Another comparator, J&J's Balversa, demonstrated an 89% complete remission rate in a clinical trial for non-muscle invasive disease, setting a high bar for dabogratinib.
• Despite the initial disappointment, analysts remain optimistic about dabogratinib's potential, particularly for a planned Phase 3 trial in the adjuvant setting to prevent cancer recurrence. They highlighted that the drug showed greater efficacy in patients with a single marker lesion (6 of 8 achieved complete remission at the highest dose) and praised its favorable safety profile, with no patients dropping out or pausing dosing due to severe side effects.

Dabogratinib's Phase 2 Efficacy and Safety in Bladder Cancer

Several recent studies have examined the efficacy and safety of key interventions in urothelial carcinoma, offering meaningful insights for clinical and strategic decision-making.

The GUARDIANS study, a retrospective multicenter analysis across 25 German hospitals, evaluated enfortumab vedotin plus pembrolizumab (EVP) as first-line treatment in 468 patients with metastatic or locally advanced urothelial carcinoma. The overall response rate (ORR) was 50.2% (complete response: 12.8%; partial response: 37.4%), with a median progression-free survival (PFS) of 10.2 months (95% CI, 8.0–12.7). Twelve-month and 24-month overall survival (OS) rates were 71.9% and 60.6%, respectively. Any-grade adverse events (AEs) occurred in 81.8% of patients, with grade ≥3 AEs in 35.8%. Peripheral sensory neuropathy and skin toxicity were the most common AEs, and ten treatment-related fatal events were recorded. Skin toxicity was associated with superior ORR, PFS, and OS.

The phase III EV-302 study similarly assessed enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Across prespecified subgroups, EV+P demonstrated OS benefit consistent with the intention-to-treat population, including patients with liver metastases (OS 19.1 versus 10.1 months), patients without liver metastases (OS not estimable versus 17.9 months), patients with visceral metastases (OS 25.6 versus 13.6 months), and patients with lymph node-only disease (OS not estimable versus 27.5 months). Confirmed objective response rate and PFS benefit with EV+P versus chemotherapy were seen across all examined subgroups. The exploratory KEYNOTE-361 analysis, evaluating pembrolizumab with gemcitabine-platinum doublet, suggested trends toward OS and PFS improvements with the addition of pembrolizumab regardless of whether cisplatin or carboplatin was the chosen platinum agent, though the primary endpoints of PFS and OS were not met. In the cisplatin-based arms, median OS was 20.1 versus 16.4 months (HR 0.88, 95% CI, 0.67–1.15) and ORR was 64.1% versus 48.7% with versus without pembrolizumab, respectively.

Dabogratinib's Position in the Bladder Cancer Treatment Landscape

In the neoadjuvant setting for muscle-invasive bladder cancer (MIBC), both dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) and perioperative durvalumab plus gemcitabine-cisplatin (D-GC) have demonstrated improved overall survival versus gemcitabine-cisplatin (GC) alone, each with a hazard ratio of 0.75 (ddMVAC: 95% CI 0.58–0.98, p = 0.034; D-GC: 95% CI 0.66–0.85, p < 0.001), with no statistically significant difference between ddMVAC and D-GC (HR 0.99, 95% CI 0.75–1.33, p = 0.97). D-GC achieved a higher pathological complete response (pCR) versus GC (OR 1.57, 95% CI 1.21–2.03, p < 0.001), whereas ddMVAC did not reach significance on this endpoint. A single-institution retrospective study of 120 patients corroborated these findings, reporting a pCR rate of 38.59% for ddMVAC versus 22.22% for GC (p = 0.04), along with higher pathologic downstaging rates (59.64% vs. 44.44%), though median overall survival did not differ significantly (41.6 months vs. 36.8 months; p = 0.12; HR 0.82, 95% CI 0.63–1.06). Grade ≥3 toxicity was more frequent with ddMVAC (35% vs. 15.87%), including febrile neutropenia in 14% versus 4.76% of patients.

For cisplatin-ineligible patients, a multicenter evaluation of 747 patients found that gemcitabine-carboplatin (gem-carbo) produced a pCR rate of 20.7% compared with 22.1% for gemcitabine-cisplatin (gem-cis), with no statistically significant difference in pCR (OR 0.99, 95% CI 0.61–1.59, p = 0.96), overall survival (HR 1.20, 95% CI 0.85–1.67, p = 0.31), or cancer-specific survival (HR 1.35, 95% CI 0.93–1.96, p = 0.11). Median OS was 28.6 months for gem-carbo versus 45.1 months for gem-cis, and median cancer-specific survival was 28.8 months versus 71.0 months (p = 0.02), though the overall survival difference did not reach statistical significance. In the advanced or metastatic setting, erdafitinib demonstrated improved outcomes versus chemotherapy in FGFR-altered metastatic urothelial carcinoma in the THOR trial, with a median OS of 12.1 versus 7.8 months and a 36% reduction in risk of death (HR 0.64, p = 0.005). In the Japanese subgroup of THOR Cohort 1, erdafitinib showed a median OS of 25.4 versus 12.4 months, median progression-free survival of 8.4 versus 2.9 months, and an objective response rate of 57.1% versus 15.4% compared with chemotherapy.

In the non-muscle-invasive bladder cancer (NMIBC) setting, a systematic review and cost-effectiveness analysis of BCG-unresponsive patients estimated a 3-month overall response rate of 52.4% (95% CI: 45.4–59.2) across bladder-sparing strategies. Among FDA-approved treatments modeled over a 2-year horizon, pembrolizumab dominated other strategies by being both less costly and more effective, while nadofaragene firadenovec was cost effective at a willingness-to-pay threshold of 100,000 USD with an incremental cost-effectiveness ratio of 10,014 USD per quality-adjusted life year, and nogapendekin alfa inbakicept had an incremental cost-effectiveness ratio of 44,602 USD per quality-adjusted life year. A network meta-analysis simulation suggested that enfortumab vedotin plus pembrolizumab (EV-P) would need to achieve an HR ≤ 0.45 versus GC to outperform both ddMVAC and D-GC in the neoadjuvant MIBC setting, underscoring the substantial efficacy threshold that emerging regimens must clear to displace established standards of care.

Refining Patient Selection for Dabogratinib's Adjuvant Phase 3

The patient selection strategy evaluated in the SURF301 study (NCT05544552) — the ongoing first-in-human, phase I/II trial of dabogratinib (TYRA-300) — centers on FGFR3 molecular alterations as the primary enrollment criterion. Specifically, patients with advanced metastatic urothelial carcinoma harboring an FGFR3 fusion or activating mutation were enrolled. The three reported patient cases from SURF301 each carried one of these FGFR3 alterations, and early clinical activity was demonstrated in this biomarker-selected population.

Preclinical work further informed the rationale for this selection strategy. Dabogratinib elicited dose-dependent reduction in downstream signaling across three bladder cancer cell lines harboring an FGFR3 fusion, mutation, or gatekeeper resistance mutation. In a xenograft model driven by an FGFR3 S249C activating mutation, dose-dependent tumor growth inhibition was observed, with tumor regression at the highest doses. These findings collectively support FGFR3 fusion and activating mutation status as the central biomarker framework guiding patient selection in dabogratinib trials.

The knowledge base does not have sufficient information on this aspect.

Dabogratinib's NMIBC Journey: A Targeted Path Forward

The recent market reaction to dabogratinib's Phase 2 results in non-muscle invasive bladder cancer (NMIBC) highlights the high expectations placed on novel targeted therapies. While a 57% complete response rate might seem promising in many oncology settings, the market's nearly 20% share drop reflects a comparison against an ambitious internal target of 70% and the efficacy of existing treatments like UroGen Pharma's Zusduri (78% remission) and Johnson & Johnson's Balversa (89% remission in a similar setting). However, this initial market sentiment may not fully capture the nuanced potential of dabogratinib.

NMIBC remains a challenging disease, characterized by high recurrence rates and a significant burden from repeated surgical procedures and intravesical therapies. The NCI has long emphasized the need for molecularly targeted and immune-based therapies, specifically identifying FGFR3 inhibitors as a priority. Erdafitinib, another FGFR inhibitor, has already demonstrated satisfactory clinical activity in metastatic urothelial carcinoma and high efficacy in FGFR3/2-altered NMIBC, with CR rates as high as 89-94% in certain cohorts, validating the FGFR pathway as a viable target.

Dabogratinib, as an oral FGFR3 inhibitor, offers a distinct advantage in terms of patient convenience compared to invasive intravesical treatments. While its CR rate may necessitate a re-evaluation of its primary indication or target population, analysts suggest a path forward, particularly in an adjuvant Phase 3 trial for patients with a single marker lesion, leveraging its favorable safety profile. The strategic implications point to a need for clear differentiation in a competitive landscape, potentially by focusing on specific NMIBC subsets or as a maintenance therapy to reduce recurrence. However, the risk remains that its efficacy, while clinically meaningful, may not be sufficiently superior to established options to secure a dominant market position. The broader challenge of translating genomic insights into widespread clinical practice in NMIBC also looms, requiring robust evidence of long-term benefit and improved patient outcomes.